We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA) is one of ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the ...

The rally came despite a broader market volatility during the period, largely due to global trade worries over the United ...

From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

The Strategy underperformed its benchmark as detractors in the consumer discretionary and communication services sector ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...

Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Every so often, activist investors swarm around underperforming companies in a certain industry and pressure them to change strategy. Right now, it’s biotech startups that are flush with cash but ...

Review the current Verona Pharma PLC ADR (VRNA:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if VRNA is the best investment for you.

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...